Removal of α-glucose residues from nascent glycoproteins in the early secretory pathway is a requirement for further N-glycan maturation. Although deglucosylation is a stepwise process mediated by endoplasmic reticulum-associated glucosidases I and II for most glycoproteins, Golgi endo-α-mannosidase provides a backup mechanism for glycoprotein deglucosylation. Although conserved in mammals, in certain cell lines, endomannosidase activity in vitro appears to differ from its activity in cells following glucosidase inhibition. Here, we show that in bovine cells this is explained by restricted substrate specificity allowing processing of Glc 1 Man 7 GlcNAc 1/2 and Glc 1 Man 5 GlcNAc 1/2 but not fully glucosylated glycans that build up when glucosidases are inhibited. Our data further demonstrate that such specificity is determined genetically rather than post-translationally. We also demonstrate that the bovine endomannosidase is transcriptionally upregulated by comparison with glucosidase II in Madin-Darby bovine kidney cells and speculate that this is to compensate for the reduced catalytic activity as measured in the recombinant form of the enzyme.
Introduction
Recent studies have underlined the importance of postendoplasmic reticulum (ER) enzymes in processing misfolded glycoproteins subsequently targeted for ER-associated degradation (ERAD) (Vashist et al. 2001; Hirayama et al. 2010; Wang and Ng 2010) . In particular, attention has been drawn to the involvement of Golgi-resident mannosidases to ERAD targeting and regulation (Bieberich et al. 1997; Lal et al. 1998; Hosokawa et al. 2007; Kukushkin et al. 2011) . We have recently demonstrated that deglucosylation of glycoproteins by Golgi endo-α-mannosidase can precede their degradation in the ER. However, for a subpopulation of misfolded substrates, such processing confers stability leading to further progression in the secretory pathway (Kukushkin et al. 2011) .
It has been known for some time that endomannosidase activity is cell-specific and varies dramatically between tissues and organisms (Karaivanova et al. 1998) . Some studies have assessed the degree of endomannosidase involvement in the processing of viral envelope glycoproteins in the presence of glucosidase inhibitors (Karaivanova et al. 1998 ). This was shown to range between complete absence of processing to essentially unimpaired deglucosylation. However, analysis of endomannosidase activity by measuring the processing of oligosaccharide substrates by various cell extracts has yielded somewhat conflicting results (Karaivanova et al. 1998) . In some cases, the measured endomannosidase activity was consistent between in vitro tests and cellular experiments, e.g. relatively high levels were demonstrated in both cases for baby hamster kidney-21 (BHK-21), BW5147 and HepG2 cells, and no activity was detected in Chinese hamster ovary-K1 (CHO-K1) cells in either of the experimental systems. However, Madin-Darby bovine kidney (MDBK) and MadinDarby canine kidney (MDCK) cells were unable to process glucosylated viral envelope glycoproteins, but demonstrated average levels of endomannosidase activity in cell extracts. This raised questions about the importance of the pathway in vivo. Since the enzyme that is present and active in the cell does not appear to be necessarily involved in glycoprotein deglucosylation, two explanations seemed likely: either endomannosidase possesses functions in addition to its deglucosylating abilities or the processing of glycoproteins by endomannosidase requires specific conditions/substrates different from those employed in the reported experimental system.
We therefore sought to investigate the specificity of endomannosidase activity in more detail to improve our understanding of its role in glycan processing and/or other cellular processes for which it may be required. In particular, we focused on MDBK endomannosidase and the apparent discrepancy between its activity in vitro and in cell culture.
Results
MDBK endomannosidase exhibits altered substrate specificity A kinetic study was conducted to assess substrate specificity of HepG2-, BHK-21-and MDBK-derived endomannosidase variants. Equal amounts of mono-, di-and triglucosylated substrates with mannose branches of varying lengths were incubated with cellular extracts. The reaction mixtures after various incubation periods were then analyzed by highperformance liquid chromatography (HPLC) as described in Materials and methods ( Figure 1A-C) . In general, endomannosidase variants preferentially processed monoglucosylated oligosaccharides with truncated mannose chains, i.e. highest levels of activity were observed for Glc 1 Man 5 GlcNAc 1 and Glc 1 Man 7 GlcNAc 1/2 in all cases. For HepG2 and BHK-21, significant rates of reaction were also observed for all oligosaccharides. Additionally, BHK-21 endomannosidase exhibited a marked preference for Glc 1 Man 5 GlcNAc 1 and Glc 1 Man 7 GlcNAc 1/2 substrates when compared with endomannosidase from HepG2 cells, as shown by the more rapid rates of hydrolysis ( Figure 1A and B). This was in accordance with previously reported data Spiro 1987, 1988) . However, the most striking observation was that MDBK endomannosidase exclusively hydrolyzed Glc 1 Man 5 GlcNAc 1 and Glc 1 Man 7 GlcNAc 1/2 ( Figure 1C) . No digestion occurred with Glc 1 Man 8 GlcNAc 1 , which was also a poor substrate for enzymes from other cell lines or any di-or triglucosylated substrate ( Figure 1C) .
The reaction rate of MDBK endomannosidase with Glc 1 Man 5 GlcNAc 1 increased with substrate concentration in a linear fashion ( Figure 1D ), indicating that the enzyme was not We then asked whether similar specificity could be observed in kidney-derived cell lines from other species. We selected three kidney cell lines: canine MDCK, human embryonic kidney 293T (HEK-293T) and rhesus monkey LLC-MK2. It is noteworthy that the enzymatic behavior of MDCK-derived endomannosidase was previously shown to be similar to that of MDBK enzyme, i.e. showing appreciable levels of activity against monoglucosylated substrates in vitro but no cellular activity following glucosidase inhibition (Karaivanova et al. 1998 ). In our in vitro assays, MDCK endomannosidase demonstrated a strong preference for monoglucosylated substrates in a manner similar to the MDBK-derived ortholog, although not as strikingly, since some digestion of Glc 3 Man 5 GlcNAc 1 was observed after 24 h of incubation (Figure 1E and F) . In contrast to these results, the triglucosylated oligosaccharide was readily digested in HEK-293T and LLC-MK2 cell extracts ( Figure 1E and F). We therefore conclude that the narrow specificity of MDBK endomannosidase is not a generalized feature of kidney-derived cell lines.
MDBK substrate specificity is determined genetically
In order to investigate whether the distinctive enzymatic properties of MDBK are determined genetically or by additional cellular factors, we cloned and expressed both human and MDBK endomannosidase variants, each with an N-terminal His-tag, in Escherichia coli.
Western blotting of bacterial lysates showed a single band of 50 kDa after 30 min of induction, although severe product fragmentation occurred after 2 h ( Figure 2A ). This band deviated from the predicted molecular weight of 52 kDa; however, when the human enzyme was expressed with an additional C-terminal hemagglutinin (HA) tag, both N-and C-terminal tags were detectable by immunoblotting, confirming expression of the full-length protein ( Figure 2B ). Similar deviation from predicted molecular weight had been observed following expression of full-length human endomannosidase in CHO-K1 cells (Kukushkin et al. 2011) .
We then assayed hMANEA and bMANEA (mannosidase, endo-alpha) protein preparations (10 ng/reaction) for activity using Glc 1 Man 5 GlcNAc 1 or Glc 3 Man 5 GlcNAc 1 (1 pmol/reaction). hMANEA was highly active and rapidly digested both the mono-and the triglucosylated substrates ( Figure 2C ). In contrast, bMANEA demonstrated low enzymatic activity and only hydrolyzed Glc 1 Man 5 GlcNAc 1 , confirming the hypothesis that the substrate specificity of endomannosidase in MDBK cells is determined genetically.
To test the possibility that the altered activity was a consequence of mutations in the MANEA gene acquired in MDBK cells since the time of their derivation from bovine kidney tissue, we sequenced the MANEA open reading frame (ORF) in cDNA from the bovine kidney, lung and liver tissue samples (Supplementary data, Table S1 ). Alignment of the protein sequences showed complete conservation between the MDBK, bovine lung and liver (Supplementary data, Figure S1 ). In the kidney, a single L95P substitution was found. We are therefore confident that endomannosidase derived from MDBK cells represents the wild-type bovine enzyme.
Defective endomannosidase is upregulated in MDBK cells
While the in vitro substrate specificity of bMANEA agreed with that demonstrated for endomannosidase in MDBK extracts, the level of Glc 1 Man 5 GlcNAc 1 hydrolysis appeared to be greatly diminished when compared with that of hMANEA ( Figure 2C ). In cell extracts, however, the rates of hydrolysis of monoglucosylated glycans did not differ greatly between MDBK and HepG2 cell lines ( Figure 1A ). We speculated that in MDBK cells, the low enzymatic activity of the defective bovine endomannosidase could be compensated for by upregulating enzyme expression. Testing this hypothesis at the post-translational level was problematic due to a lack of commercially available antibody that specifically identified endogenous endomannosidase in cells (Kukushkin et al. 2011 ) and the difficulty of quantitatively staining the enzyme variants from two different cell lines. We therefore employed quantitative polymerase chain reaction (qPCR) to evaluate MANEA mRNA levels. As internal standards, we used both glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene, and glucosidase II α-subunit (GANAB), employed to standardize the levels of endomannosidase within the secretory pathway. Since the transcript levels were assayed in two different cell lines, using an internal standard within the same pathway allowed correcting for functional differences, e.g. varying abundance of secretory pathway machinery, in general. For this purpose, glucosidase II is an ideal control for endomannosidase, since the two enzymes mediate the primary and backup route for deglucosylation of N-linked oligosaccharides, respectively.
We first carried out semiquantitative reverse transcriptase-PCR (RT-PCR) in order to optimize reaction conditions and primer specificity. Relative band intensities following amplification of MANEA or GANAB transcript fragments confirmed that the endomannosidase/glucosidase II ratios were elevated in MDBK cells when compared with HepG2 cells ( Figure 3A) . Control PCR amplifying a fragment of the β-actin gene spanning a short intron confirmed that cDNA was the template ( Figure 3A) . MANEA, GANAB and GAPDH transcript levels were then measured by qPCR ( Figure 3B ). When MANEA levels were normalized to GAPDH, an increase was observed in MDBK cells but did not reach significance ( Figure 3C ). However, when GANAB was used as the standard, the ratio between the two deglucosylating enzymes was shown to be significantly shifted towards endomannosidase by 6.6-fold ( Figure 3C ). Overall, we observed a trend towards transcriptional upregulation of endomannosidase in MDBK cells that may compensate for the reduced enzymatic activity of a substrate-restricted enzyme. This upregulation shown may not be the full explanation, since many cellular factors may contribute to an increase in steady-state levels of enzyme activity, but partial restoration of enzymatic efficiency without a change in substrate specificity at the level of transcription is one conclusion that can be drawn.
Discussion
In the present study, we aimed to clarify the conflicting data on the cellular activity of endomannosidase. In certain cell lines such as MDBK, endomannosidase is incapable of compensating for glucosidase inhibition imposed by glucosidase inhibitors such as castanospermine or N-butyldeoxynojirimycin (NB-DNJ). It does, however, remain active in in vitro experiments (Karaivanova et al. 1998) . The apparent contradiction between these two findings raised questions, particularly intriguing in light of our findings that endomannosidase could interact with glycoproteins prior to their retrograde transport to the ER followed by degradation (Kukushkin et al. 2011) . Since endomannosidase appeared to be conserved independent of its enzymatic function, it was tempting to speculate that the protein could have some additional nonglycosidase role. On the other hand, the fact that MDBK endomannosidase enzymatic activity was unavailable for at least some glycoproteins in the secretory pathway was puzzling and further challenged the established view on endomannosidase as a nonselective post-ER deglucosylation system (Torossi et al. 2006) . 
Restricted processing of glycans by endomannosidase
The resolution of these contradictions lies in substrate specificity. Following glucosidase inhibition, the majority of newly synthesized glycoproteins remain in the triglucosylated state. Although most variants of endomannosidase appear to be capable of processing such substrates, MDBK endomannosidase demonstrates genetically determined strict specificity for monoglucosylated glycans. These had been used as substrates in the previously reported in vitro experiments (Karaivanova et al. 1998) . The fact that MDBK endomannosidase is apparently incapable of deglucosylating glycoproteins in glucosidase-inhibited cells does not therefore point to cellspecific differences in protein function or localization, but merely reflects the triglucosylated status of ER-exported substrates under these conditions.
It is noteworthy that the number of glucose residues is not the only limiting factor for MDBK endomannosidase, since only substrates with fewer than eight mannose residues were processed by the enzyme. What is the biological significance of such extreme substrate specificity compared with enzyme variants from other organisms? Endomannosidase is mainly distributed between cis-and medial-Golgi (Zuber et al. 2000; Torossi et al. 2010; Kukushkin et al. 2011) . At this stage, the vast majority of glucosylated oligosaccharides have been processed by ER and Golgi mannosidases to the end structure of Glc n Man 7 GlcNAc 2 . In cells treated with high concentrations of glucosidase inhibitors, this takes the form of Glc 3 Man 7 GlcNAc 2 , the major N-linked oligosaccharide on secreted proteins. However, in normal conditions, the vast majority of endomannosidase substrates would be represented by monoglucosylated oligosaccharides, specifically Glc 1 Man 7 GlcNAc 2 . It is therefore likely that the narrow specificity of bovine endomannosidase does not affect its ability to carry out its physiological function.
At the same time, we have shown that bovine endomannosidase is characterized not only by limited specificity, but also by reduced activity. In MDBK cell extracts, however, the rates of Glc 1 Man 7 GlcNAc 2 processing were close to those of other cell lines. This was likely due to increased expression of the enzyme in the cell, as evidenced by the increase in endomannosidase/glucosidase II mRNA ratio. Taken together, our data point to the evolutionary requirement for unimpaired processing rates of Glc 1 Man 7 GlcNAc 2 but not of other glucosylated glycans.
The precise nature of the altered enzymatic properties of MDBK endomannosidase remains to be elucidated. While our studies indicate that the specificity of bovine enzyme is genetically determined, the residues responsible are uncertain as sequence alignment shows that all amino acids required for catalysis or substrate binding (Thompson et al. 2012 ) are conserved across mammalian species (Supplementary data, Figure S2 ). While this manuscript was in preparation, Thompson et al. (2012) published an X-ray diffraction structure of two bacterial orthologs of mammalian endomannosidase. Homology modeling (Arnold et al. 2006 ) of human and bovine enzymes using the published structure of Bacteroides xylanisolvens reveals a serine-to-lysine substitution at position 227 (226 in bMANEA) (Supplementary data, Figure S2 ) in the vicinity of the active site. The substitution results in the bulky lysine side chain protruding into the substrate-binding groove and possibly obstructing access for oligosaccharides bearing more than a single glucose residue. This serine residue is relatively conserved in mammals, although the same substitution to lysine is predicted for pigs based on genomic data (Supplementary data, Figure S2 ). It is tempting to speculate that the substitution may also be present in other Artiodactyla. Future work would include mutational studies to further characterize the structural basis for, and the importance of, endomannosidase selectivity.
Materials and methods

Endomannosidase assay
Oligosaccharide substrates were isolated and purified from MDBK cells treated with NB-DNJ for 24 h as described previously (Alonzi et al. 2008; Butters et al. 2009 ). For enzyme assays, cell homogenates were centrifuged at 600 × g for 10 min, followed by centrifugation of supernatants at 135,000 × g for 20 min. Pellets were then resuspended in 4-morpholineethanesuphonic acid, sodium salt (NaMES) buffer, 0.1 M, pH 6.5, to a total protein concentration of 15 mg/mL. Following a 1 h preincubation at 37°C with 0.2% Triton X-100, 10 mM ethylenediaminetetraacetic acid (EDTA) and 2 mM of each NB-DNJ and deoxymannojirimycin, 1 pmol 2-anthranilic acid-labeled free oligosaccharide substrates were added to the reaction mixture (final reaction volume of 21 µL). Reaction products were separated by normal-phase-HPLC (NP-HPLC) using the previously reported conditions and detected using an inline fluorescence detector (Neville et al. 2004 ).
Construction of plasmids for bacterial expression
Truncated human endomannosidase ORF (hMANEA) was amplified from an IMAGE cDNA clone in a pCR4 plasmid (IMAGE:9021009, GenBank ® BC137016.1; Geneservice) using the primers: 5′-TATATAAGAATCCATATGGGTTTAAAAATGCTGAGAC CAAATACAGC-3′ 5′-ATAATTGTAGCTCGAGTCCAGAACTCAAAACGAAA GC-3′
For a construct containing a C-terminal hemagglutinin tag (hMANEA-HA), the reverse primer was replaced with the following:
The resulting product was gel-purified and digested with NdeI and XhoI, and the fragment obtained was ligated into the pET15b expression vector following gel purification of both digested vector and insert.
Amplification of MDBK MANEA ORF Total RNA was isolated from trypsinized, phosphate-buffered saline-washed, pelleted MDBK cells using TRI reagent (Sigma, UK) following manufacturer's instructions. For 3′-end amplification, cDNA was synthesized using a dT 12 -AP primer (5′-GACTCGAGTCGACATCGTTTTTTTTTTTT-3′). 3′RACE (rapid amplification of cDNA ends) procedure (Frohman et al. 1988 ) was carried out with a gene-specific forward primer NV Kukushkin et al. (P1: 5′-CCCAAAGGGAAGCACAACCCCC-3′) and an adaptor primer (AP: 5′-GACTCG AGTCGA CATCG-3′) using a gradient of annealing temperatures (50-60°C) and extended first-cycle DNA synthesis time. Nested PCR was carried out on the obtained product using P1 as a forward primer and an extra gene-specific reverse primer designed to anneal to the 3′-untranslated region (UTR) of the cDNA (P2: 5′-CCCATA ACCCAAAACAAAAGG-3′).
For 5′-end amplification, cDNA was synthesized using the P2 primer. The desired fragment was amplified using direct PCR, using a forward primer annealing to the predicted 5′-UTR (P3: 5′-CCATTTTGGAGTTTAAAGGATGA-3′) and a reverse primer other than P2 (P4: 5′-TCCTGGGCCCACA CTTGGGA-3′). The complete ORF was obtained by ligating the two fragments using a unique BamHI restriction site located within the overlap. The resulting sequence, termed bMANEA, was then cloned into the pET15b vector as described for hMANEA.
Endomannosidase expression in E. coli BL21/DE3 E. coli competent cells (Stratagene, UK) were transformed with pET15b-hMANEA, pET15b-bMANEA or pET15b-hMANEA-HA according to the manufacturer's instructions. Induction was carried out for 30 min or 2 h, followed by rapid cooling of the cultures to 4°C. Bacterial pellets were lysed, inclusion bodies purified and dissolved in a buffer containing guanidine-HCl (GdHCl; 6 M) and β-mercaptoethanol (100 mM). After an overnight incubation at room temperature, the obtained solutions were diluted 10-fold in 0.1 M sodium phosphate buffer, pH 8.0, containing GdHCl (6 M), NaCl (0.5 M), imidazole (10 mM) and β-mercaptoethanol (10 mM). His-tagged proteins were purified using a HisTrap HF column (5 mL cartridge; GE Healthcare, UK) and pH-dependent elution. Refolding was carried out at 4°C by slowly diluting eluted GdHCl-solubilized protein at least 100-fold (to 30-50 μg/mL) in 100 mM Tris-HCl buffer, pH 8.0, containing 400 mM L-arginine, 2 mM NaEDTA, 5 mM reduced glutathione and 0.02% (w/v) sodium azide, followed by overnight stirring. The solution was sterile-filtered, concentrated using an Amicon nitrogen pressure concentrator with a YM30 membrane and then subjected to extensive dialysis against 50 mM Tris-HCl, pH 8.0 or 100 mM NaMES, pH 6.5, at 4°C. Samples were then further concentrated in Amicon microconcentrators (10 kDa cut-off filters) and 0.1 µg aliquots of the enzymes was lyophilized for later use in enzyme assays.
Quantitative PCR cDNA was synthesized as described above, and semiquantitative or qPCR was carried out using Phusion High-Fidelity DNA Polymerase Kit or DyNAmo™ SYBR ® Green qPCR Kit (NEB, UK), respectively, according to the manufacturer's instructions. Gene-specific primers were used for semiquantitative and/or qPCR (Supplementary data, Table S1 ). For qPCR, amplification efficiencies (E) were determined by serial dilutions of the template. Threshold cycle (C t ) values were calculated using Opticon Monitor 2 software. Absolute amounts of cDNA were determined as ð1 þ EÞ ÀC t , and MANEA/GANAB or MANEA/GAPDH ratios calculated from the values obtained.
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